The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 3, randomized study of adjuvant sacituzumab tirumotecan plus pembrolizumab vs treatment of physician’s choice in participants with triple-negative breast cancer who received neoadjuvant therapy and did not achieve a pathologic complete response at surgery.
 
Heather McArthur
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; Merck; Moderna Therapeutics; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
 
Rebecca Dent
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; DKSH; Eisai; Gilead Sciences; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai; Gilead Sciences; MSD; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai; MSD; Novartis; Pfizer; Roche
 
Rina Hui
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Janssen; Johnson & Johnson/Janssen; Lilly; Merck Sharp & Dohme; Novartis
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Eisai; Janssen Oncology; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Oncosec; Pfizer; Roche; Seagen
Research Funding - AstraZeneca (Inst); BMSi (Inst); Corvus Pharmaceuticals (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); OncoSec (Inst); Roche (Inst); Seagen (Inst)
 
Yeon Hee Park
Honoraria - AstraZeneca; Daiichi-Sankyo; Eisai; Gilead Sciences; Helsinn Healthcare; Lilly; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boryung; Daiichi-Sankyo; Eisai; Gilead Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Roche
Research Funding - AstraZeneca; Gencurix (Inst); Inocras (Inst); NGeneBio (Inst); Pfizer; Roche (Inst)
Travel, Accommodations, Expenses - Gilad
 
Peter Schmid
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Merck; Novartis; Pfizer; Puma Biotechnology; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Merck; Novartis; Pfizer; Puma Biotechnology; Roche
Research Funding - Astellas Pharma; AstraZeneca; Genentech; Medivation; Merck; Novartis; OncoGenex; Roche
 
Jing Wei
No Relationships to Disclose
 
Jaime Mejia
Employment - University of Pennsylvania (I)
Stock and Other Ownership Interests - Merck
Honoraria - Merck
 
Wilbur Pan
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Javier Cortes
Stock and Other Ownership Interests - Leuko (I); MAJ3 Capital
Honoraria - AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung; Steamline Therapeutics
Consulting or Advisory Role - Abbvie; AstraZeneca; Athenex; Bioasis; Biocon; Bioinvent; BioNTech SE; Boehringer Ingelheim; Bridgebio; Celgene; Cellestia Biotech; Circle Pharma; Clovis Oncology; Daiichi Sankyo; Delcath Systems; Ellipses Pharma; ERYTECH Pharma; Expres2ion Biotechnologies; GEMoaB; Gilead Sciences; GlaxoSmithKline; Hexagon Bio; HiberCell; Jazz Pharmaceuticals; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks
Research Funding - ARIAD (Inst); Astrazeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Merck Sharp&Dhome; Novartis; Pfizer; Roche; Steamline Therapeutics